IBD patients are often told that our understanding of the GI tract and how to improve patient care improves every day, but the real challenge is ensuring that this knowledge reaches the people who need it most; the doctors and specialists working day-in and day-out to bolster the field through their research and hard work.
This year at the Advances in Inflammatory Bowel Diseases (AIBD) Conference in Orlando, over 2,500 medical professionals, biotechnologists, and researchers gathered to hear about the CurQD® Protocol, Evinature’s flagship nutraceutical. CurQD® took the spotlight not once, not twice, but three separate times, with global experts highlighting CurQD® in their keynote presentations. This recognition solidifies CurQD®’s position as a revolutionary new treatment for improving IBD.
CurQD®: The Highlight of AIBD 2024
The AIBD Conference gathers internationally recognized experts in gastroenterology from across the globe to discuss advancements and solutions to treat inflammatory bowel disease (IBD). Thousands of attendees, varying from start-ups to researchers, convened for 3 days, pitting their innovations against each other to gain awareness for their ideas and treatments. Amid this competitive environment, CurQD®’s efficacy and clinical significance stole the show, with renowned speakers presenting studies underscoring the nutraceutical’s role in transforming IBD management through safe and natural approaches.
Recognized by Leading Experts
Dr. Maia Kayal: Dr. Kayal, Assistant Professor of Gastroenterology at the Icahn School of Medicine at Mount Sinai, presented groundbreaking research published in the Journal of Crohn’s and Colitis. The study she presented focused on CurQD®’s effectiveness in reducing bowel urgency, one of the most debilitating symptoms of IBD. Results showed that 70% of participants experienced significant improvements in bowel urgency, offering a natural, clinically proven solution to enhance patients’ quality of life.
Dr. Bruce Sands: An internationally recognized expert and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai, Dr. Sands showcased our multicenter, randomized, double-blind, placebo-controlled study on CurQD®. The research demonstrated CurQD®’s clear advantage in combination therapy for active ulcerative colitis. The findings emphasized CurQD®’s potential to complement existing treatments, making it a pivotal tool in enhancing IBD care and management.
Dr. Dawn B. Beaulieu: Founder of the first Functional Medicine IBD Clinic in the U.S. and an Associate Professor at Vanderbilt University, Dr. Beaulieu highlighted the recently published benefits of CurQD® in pediatric ulcerative colitis treatment. Her presentation emphasized the protocol’s role in reducing gut inflammation, improving restoration, and transforming the quality of life for young patients.
A Testament to Innovation
Evinature’s mission is to revolutionize IBD patient care through cutting-edge, plant-based nutraceuticals backed by robust clinical research. The spotlight on CurQD® at AIBD reflects the culmination of years of dedicated research and collaboration. Dr. Shomron Ben-Horin, Evinature’s Chief Medical Officer and co-founder, encapsulated this achievement, saying, “It has been a long journey of CurQD® research. Evinature has matured to bring a novel plant-based agent to help IBD patients all over the globe!”
Looking Ahead
Through increasing awareness and continued research, Evinature aims to expand access to CurQD® and its benefits for more IBD patients worldwide. Backed by high-quality studies and endorsed by leading experts, CurQD® stands at the forefront of innovative IBD treatments. As demonstrated at AIBD, the future of IBD patient care is here, and Evinature is honored to be able to change the lives of thousands worldwide.
Summer Pitocchelli-Schwartzman
